Concert Pharmaceuticals, Inc. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
Concert Pharmaceuticals, Inc. reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2022-11-07
- Concert Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2022-09-30 was $0.00.
- Concert Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2022-06-30 was $497.00K.
- Concert Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2021-09-30 was $0.00.
- Concert Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for the quarter ending 2021-06-30 was $0.00.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 3 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 6 month | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 | $497.00K derived: sum of 2 quarters · filed 2022-11-07 | $373.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $497.00K 10-Q · filed 2022-08-04 | $497.00K 10-Q · filed 2022-08-04 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 |